(F) Expression level of our genes (median) in cutaneous melanoma biopsies before the BRAFi-treatment (baseline) and during the relapse. The expression level of our BRAFi-resistance genes is increased in relapse samples (48%, n=21). (G) Expression level of our genes (median) in cutaneous melanoma biopsies before the BRAFi-treatment and during the relapse. The expression level of our BRAFi-resistance genes is increased in relapse samples (31%, n=16). 